Open AccessAdvances in the treatment of acute graft‐versus‐host disease
Author(s) -
Qian Liren,
Wu Zhengcheng,
Shen Jianliang
Publication year - 2013
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12093
Subject(s) - medicine , hematopoietic stem cell transplantation , immunology , disease , graft versus host disease , pathogenesis , immune system , stem cell , transplantation , pathology , biology , genetics
Allogeneic hematopoietic stem cell transplantation ( HSCT ) has been widely used for the treatment of hematologic malignant and non‐malignant hematologic diseases and other diseases. However, acute graft‐versus‐host disease ( GVHD ) is a life‐threatening complication of allogeneic transplantation. Acute GVHD may occur in 30% of transplant recipients, which is a syndrome of erythematous skin eruption, cholestatic liver disease and intestinal dysfunction, resulting from the activation of donor T lymphocytes by host antigen‐presenting cells, resulting in an immune‐mediated inflammatory response. Recent scientific advances in the understanding of the pathogenesis involved in the development of acute GVHD and clinical investigation have provided more effective therapeutic strategies for acute GVHD . This review focuses on major scientific and clinical advances in the treatment of acute GVHD .